Menu

Blog

Archive for the ‘genetics’ category: Page 299

May 20, 2020

First clinical trial with genetically modified malaria vaccine completed

Posted by in categories: biotech/medical, genetics

In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.

Malaria is a major infectious disease, caused by a parasite with a complicated life cycle in humans and mosquitoes. The in humans takes place in the liver, the second in the blood. Since the liver phase does not cause any symptoms of disease, but the blood phase does, the purpose of the vaccine is to stop the parasite in the liver.

May 20, 2020

Scientists enlist cattle to create potential COVID-19 drug

Posted by in categories: bioengineering, biotech/medical, genetics

INDIANAPOLIS (WISH) — First is was monkeys, then dogs.

Now, researchers are turning to cows in hopes of developing a treatment for the coronavirus.

Scientists at SAb Biotherapeutics in South Dakota created an embryo via genetic engineering that contains human chromosomes. The embryo was then implanted into cattle. The cows gave birth to calves that internally function similarly to a person, specifically with regards to the human immune system.

May 19, 2020

Colonizing Mars may require humanity to tweak its DNA

Posted by in categories: biotech/medical, genetics

Genetic enhancement could allow humanity to push surprisingly far out into the final frontier.

Colonizing Mars may require humanity to tweak its DNA :

May 18, 2020

National Lab Scientists Work to Reprogram Genes to Fight COVID-19

Posted by in categories: biotech/medical, engineering, genetics

Using CRISPR, Sandia National Lab researchers are genetically engineering antiviral countermeasures to fight the coronavirus—and potentially future outbreaks.

May 18, 2020

New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair

Posted by in categories: biotech/medical, genetics

The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicine demonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.

Androgenetic alopecia (AGA) — commonly known as male-pattern baldness (female-pattern baldness in women) — is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a person’s self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.

Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.

May 18, 2020

The Biological Singularity

Posted by in categories: biotech/medical, genetics, robotics/AI, singularity

Circa 2010 what someday we could use crispr to develop a biology singularity to find the epigenetics to evolve at lightning speed.


If you’re a sci-fi reader, you are probably familiar with the idea of the “technological singularity”. For the uninitiated, the Singularity is the idea that computational power is increasing so rapidly that soon there will be genuine artificial intelligence that will far surpass humans. Essentially, once you have smarter-than-human computers, they will drive their own advancement and we will no longer be able to comprehend the technology.

We can debate whether the singularity will or will not happen, and what the consequences might be, for a long time, but that’s not the point of this post. This post was inspired by the final chapter in Denialism by Michael Specter. In that chapter, Specter talks about the rapid advancement in biotechnology. Specifically, he points to the rapid increase in computational power and the resulting rapid increase in the speed of genome processing.

May 17, 2020

Intriguing Genetics That Flipped the Food Chain to Allow Carnivorous Plants to Hunt Animals

Posted by in categories: biotech/medical, food, genetics

Plants can produce energy-rich biomass with the help of light, water and carbon dioxide. This is why they are at the beginning of the food chains. But the carnivorous plants have turned the tables and hunt animals. Insects are their main food source.

A publication in the journal Current Biology now sheds light on the secret life of the green carnivores. The plant scientist Rainer Hedrich and the evolutionary bioinformatician Jörg Schultz, both from Julius-Maximilians-Universität (JMU) Würzburg in Bavaria, Germany, and their colleague Mitsujasu Hasebe from the University of Okazaki (Japan) have deciphered and analyzed the genomes of three carnivorous plant species.

They studied the Venus flytrap Dionaea muscipula, which originates from North America, the globally occurring waterwheel plant Aldrovanda vesiculosa and the spoon-leaved sundew Drosera spatulata, which is widely distributed in Asia.

May 17, 2020

Interferon-α2b Treatment for COVID-19

Posted by in categories: biotech/medical, chemistry, genetics

The global pandemic of COVID-19 cases caused by infection with SARS-CoV-2 is ongoing, with no approved antiviral intervention. We describe here the effects of treatment with interferon (IFN)-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China. In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.) or a combination of IFN-α2b plus arbidol. Serial SARS-CoV-2 testing along with hematological measurements, including cell counts, blood biochemistry and serum cytokine levels, and temperature and blood oxygen saturation levels, were recorded for each patient during their hospital stay. Treatment with IFN-α2b with or without arbidol significantly reduced the duration of detectable virus in the upper respiratory tract and in parallel reduced duration of elevated blood levels for the inflammatory markers IL-6 and CRP. These findings suggest that IFN-α2b should be further investigated as a therapy in COVID-19 cases.

In December 2019, an outbreak of pneumonia was reported in Wuhan, Hubei province, China, resulting from infection with a novel coronavirus (CoV), severe acute respiratory syndrome (SARS)-CoV-2. SARS-CoV-2 is a novel, enveloped betacoronavirus with phylogenetic similarity to SARS-CoV (1). Unlike the coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU, that are pathogenic in humans and are associated with mild clinical symptoms, SARS-CoV-2 resembles both SARS-CoV and Middle East respiratory syndrome (MERS), with the potential to cause more severe disease. A critical distinction is that CoVs that infect the upper respiratory tract tend to cause a mild disease, whereas CoVs that infect both upper and lower respiratory tracts (such as SARS-CoV-2 appears to be) may cause more severe disease. Coronavirus disease (COVID)-19, the disease caused by SARS-CoV-2, has since spread around the globe as a pandemic.

In the absence of a SARS-CoV-2-specific vaccine or an approved antiviral, a number of antivirals are currently being evaluated for their therapeutic effectiveness. Type I IFNs-α/β are broad spectrum antivirals, exhibiting both direct inhibitory effects on viral replication and supporting an immune response to clear virus infection (2). During the 2003 SARS-CoV outbreak in Toronto, Canada, treatment of hospitalized SARS patients with an IFN-α, resulted in accelerated resolution of lung abnormalities (3). Arbidol (ARB) (Umifenovir) (ethyl-6-bromo-4-[(dimethylamino)methyl]-5-hydroxy-1-methyl-2 [(phenylthio)methyl]-indole-3-carboxylate hydrochloride monohydrate), a broad spectrum direct-acting antiviral, induces IFN production and phagocyte activation. ARB displays antiviral activity against respiratory viruses, including coronaviruses (4).

May 16, 2020

Lizard genome sequence solves a human genetic mystery

Posted by in categories: biotech/medical, genetics

Circa 2011


320 million years ago, mammals and reptiles reached an evolutionary parting of the ways. We’ve now sequenced a lizard genome for the first time ever, and it’s vastly different from our own…but in a few crucial ways, it’s shockingly similar.

May 16, 2020

The claustrum coordinates cortical slow-wave activity

Posted by in categories: genetics, neuroscience

During sleep and awake rest, the neocortex generates large-scale slow-wave (SW) activity. Here, we report that the claustrum coordinates neocortical SW generation. We established a transgenic mouse line that enabled the genetic interrogation of a subpopulation of claustral glutamatergic neurons. These neurons received inputs from and sent outputs to widespread neocortical areas. The claustral neuronal firings mostly correlated with cortical SW activity. In vitro optogenetic stimulation of the claustrum induced excitatory postsynaptic responses in most neocortical neurons, but elicited action potentials primarily in inhibitory interneurons. In vivo optogenetic stimulation induced a synchronized down-state featuring prolonged silencing of neural activity in all layers of many cortical areas, followed by a down-to-up state transition. In contrast, genetic ablation of claustral neurons attenuated SW activity in the frontal cortex. These results demonstrate a crucial role of claustral neurons in synchronizing inhibitory interneurons across wide cortical areas for the spatiotemporal coordination of SW activity.